Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.

Kim MC, Lee JS, Kwon YM, O E, Lee YJ, Choi JG, Wang BZ, Compans RW, Kang SM.

Antiviral Res. 2013 Sep;99(3):328-35. doi: 10.1016/j.antiviral.2013.06.010. Epub 2013 Jun 27.

2.

Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Kim MC, Song JM, O E, Kwon YM, Lee YJ, Compans RW, Kang SM.

Mol Ther. 2013 Feb;21(2):485-92. doi: 10.1038/mt.2012.246. Epub 2012 Dec 18.

3.

Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.

Kim MC, Lee YN, Hwang HS, Lee YT, Ko EJ, Jung YJ, Cho MK, Kim YJ, Lee JS, Ha SH, Kang SM.

Vaccine. 2014 Oct 7;32(44):5824-31. doi: 10.1016/j.vaccine.2014.08.030. Epub 2014 Aug 27.

4.

Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.

Lee YN, Kim MC, Lee YT, Kim YJ, Lee J, Kim C, Ha SH, Kang SM.

Antiviral Res. 2015 Oct;122:82-90. doi: 10.1016/j.antiviral.2015.08.001. Epub 2015 Aug 4.

PMID:
26248203
5.

Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.

Lee YN, Lee YT, Kim MC, Hwang HS, Lee JS, Kim KH, Kang SM.

Immunology. 2014 Oct;143(2):300-9. doi: 10.1111/imm.12310.

6.

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.

Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK.

PLoS One. 2011;6(11):e27953. doi: 10.1371/journal.pone.0027953. Epub 2011 Nov 30.

7.

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.

Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W.

J Virol. 2005 Jun;79(11):6644-54.

8.

Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.

Music N, Reber AJ, Kim MC, York IA, Kang SM.

Vaccine. 2016 Jan 20;34(4):466-73. doi: 10.1016/j.vaccine.2015.12.023. Epub 2015 Dec 19.

9.

Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice.

Wang L, Wang YC, Feng H, Ahmed T, Compans RW, Wang BZ.

Biomed Res Int. 2013;2013:686549. doi: 10.1155/2013/686549. Epub 2013 Jul 30.

10.

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Zheng BJ, Zhou Y.

Virol J. 2010 Jul 12;7:151. doi: 10.1186/1743-422X-7-151.

11.

Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Kim MC, Lee JW, Choi HJ, Lee YN, Hwang HS, Lee J, Kim C, Lee JS, Montemagno C, Prausnitz MR, Kang SM.

J Control Release. 2015 Jul 28;210:208-16. doi: 10.1016/j.jconrel.2015.05.278. Epub 2015 May 21.

12.

Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.

Kim MC, Lee YN, Ko EJ, Lee JS, Kwon YM, Hwang HS, Song JM, Song BM, Lee YJ, Choi JG, Kang HM, Quan FS, Compans RW, Kang SM.

Mol Ther. 2014 Jul;22(7):1364-74. doi: 10.1038/mt.2014.33. Epub 2014 Mar 4.

13.

A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.

Lee YN, Lee YT, Kim MC, Gewirtz AT, Kang SM.

J Immunol. 2016 Mar 15;196(6):2637-45. doi: 10.4049/jimmunol.1501637. Epub 2016 Feb 10.

PMID:
26864033
15.

Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.

Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T.

PLoS One. 2012;7(9):e45765. doi: 10.1371/journal.pone.0045765. Epub 2012 Sep 24.

16.

Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.

Wang BZ, Gill HS, Kang SM, Wang L, Wang YC, Vassilieva EV, Compans RW.

Clin Vaccine Immunol. 2012 Aug;19(8):1119-25. doi: 10.1128/CVI.00153-12. Epub 2012 May 30.

17.

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.

Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, Gorshkov AN, Kasyanenko MA, Ravin NV, Kiselev OI.

Vaccine. 2015 Jun 26;33(29):3398-406. doi: 10.1016/j.vaccine.2015.04.073. Epub 2015 May 11.

PMID:
25976545
18.

Influenza virus-like particles containing M2 induce broadly cross protective immunity.

Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM.

PLoS One. 2011 Jan 18;6(1):e14538. doi: 10.1371/journal.pone.0014538.

19.

Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.

Stepanova LA, Kotlyarov RY, Kovaleva AA, Potapchuk MV, Korotkov AV, Sergeeva MV, Kasianenko MA, Kuprianov VV, Ravin NV, Tsybalova LM, Skryabin KG, Kiselev OI.

PLoS One. 2015 Mar 23;10(3):e0119520. doi: 10.1371/journal.pone.0119520. eCollection 2015.

20.

Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.

Pascual E, Mata CP, Gómez-Blanco J, Moreno N, Bárcena J, Blanco E, Rodríguez-Frandsen A, Nieto A, Carrascosa JL, Castón JR.

J Virol. 2015 Mar;89(5):2563-74. doi: 10.1128/JVI.03025-14. Epub 2014 Dec 17.

Items per page

Supplemental Content

Write to the Help Desk